New co-lead investor Biovance Capital and existing co-lead investor Kurma Partners provided the latest investment.
The money will be used to further develop Laigo’s Surface Removal Targeting Chimeras (SureTACs) oncology programmes, and to advance its selected autoimmune and immunology indications, and graft rejection candidate programmes.
João Incio, General Partner at Biovance Capital, added: “Laigo Bio has shown that its SureTACs degradation technology results in remarkable in vivo and in vitro efficacy, with a high degree of selectivity and improved toxicity and safety.”
Using its proprietary SureTACs platform, Laigo can generate bispecific antibodies that pair the optimal E3 ligase with a disease-causing target protein.
This stimulates the target protein’s ubiquitination and lysosomal degradation with a high degree of specificity, allowing for the development of dual targeted therapies.
Matthew Baker, CEO of Laigo Bio, said: “The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual targeted therapies to redefine the treatment of cancer and autoimmune diseases.
“The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in auto-immunity and immunology.”
Laigo received funding from a syndicate of international investors, consisting of Kurma Partners, Biovance Capital, Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region and Cancer Research Horizons.
